

UAB MEDICAL GENOMICS LABORATORY 720 South Twentieth Street, Suite 330 Tel: (205) 934-5562 Birmingham, Alabama 35294-0005 Fax: (205) 996-2929 www.genetics.uab.edu/medgenomics				Accession: For MGL Laboratory Use only	
Test Requisition Form					
- This form must accompany all specimens received			- All specimens received must include two patient identifiers		
- Billing instructions are available on page 5			- Testing must be ordered by a qualified clinician		
Additional testing information is available at www.genetics.uab.edu/medgenomics					
Patient Information:			Ordering Physician:		
Date of specimen collection:			<input type="checkbox"/> Please check box if physician should receive report directly		
Patient Name: (First) (MI) (Last)			Name:		NPI:
DOB: (MM/DD/YY)		MRN:	Institution:		
Address:			Address:		
City:		State:	Zip:		
City:		State:	Zip:		
Gender:		SSN:	Email:		
Phone:		Email:	Phone:		Fax:
Parent or Guardian Name (if minor):			Additional Reports to		
Please list other information here:			Name		
			Address:		
City:		State:	Zip:		
City:		State:	Zip:		
Institution:		Email:			
Phone:		Fax:			
For MGL Lab Use only:			Lab/Hospital Information:		
			<input type="checkbox"/> Please check box if Lab/Hospital should receive report directly		
Received:	Initials:	Date:	Comment:	Name:	
Reviewed:				Address:	
Accession:				City: State: Zip:	
Billing:				Email:	
Other:				Phone: Fax:	
Informed Consent:					
Provider's statement: I acknowledge the risks, benefits, limitations, and implications of genetic testing as outlined on the complete informed consent handout; and I have discussed the test(s) requested with the patient/guardian and I have answered his/her questions regarding testing. Informed consent has been obtained from the patient/guardian and the hard copy will be maintained.					
Provider's Signature: _____					
Patient History (Please check all that apply)					
<input type="checkbox"/> Infectious diseases (AIDS, Hepatitis, etc.)			<input type="checkbox"/> Patient has had chemotherapy in the past 6 months		
<input type="checkbox"/> Patient has had a bone marrow transplant			<input type="checkbox"/> Patient or family member is pregnant LMP:		
Previous Testing History					
Has this patient or relatives had previous testing? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Name/Relationship to patient:			Test/Mutation/Lab:		
Name/Relationship to patient:			Test/Mutation/Lab:		



UAB MEDICAL GENOMICS LABORATORY 720 South Twentieth Street, Suite 330 Birmingham, Alabama 35294-0005 www.genetics.uab.edu/medgenomics	Accession: For MGL Laboratory Use only
Patient Name: (First) (MI) (Last)	DOB: (MM/DD/YY)
Comprehensive Testing for Constitutional/Mosaic Mutations with Deep Coverage via NGS	
If multiple tests are requested, please specify order in which testing should be performed.	
Acceptable Specimen Types <ul style="list-style-type: none"> • Blood, (3-6ml EDTA; no time limitations associated with receipt) • Saliva, (OGR-575 DNA Genotek; kits are provided upon request) • DNA, (extracted from lymphocyte cells, a minimum of 25ul at 3µg, O.D. value at 260:280nm ≥1.6, must be extracted in a CLIA or equivalent certified lab) • Fibroblasts 	Key used below: Next Generation Sequencing (NGS) Sanger Sequencing (Sanger) Deletion/Duplication analysis (Del/Dup)
<input type="checkbox"/> RUSH Analysis: Testing completed within 15 working days of receipt of sample (Additional \$600 RUSH fee applied; only available for tests listed on page 2)	
NF1/SPRED1 and Other RASopathy Related Conditions	NF2/Schwannomatosis/Meningiomatosis
<input type="checkbox"/> NF1-NG: NGS and Del/Dup: <i>NF1</i> only <input type="checkbox"/> NFSP-NG: NGS and Del/Dup: <i>NF1</i> and <i>SPRED1</i> only <input type="checkbox"/> NNP-NG: NGS 16 genes (no <i>NF1</i>): <i>BRAF, CBL, HRAS, KRAS, MAP2K1, MAP2K2, NRAS, PPP1CB, PTPN11, RAF1, RASA2, RIT1, SHOC2, SOS1, SOS2,</i> and <i>SPRED1</i> and Del/Dup: <i>SPRED1</i> <input type="checkbox"/> RAS-NG: NGS 17 genes: <i>BRAF, CBL, HRAS, KRAS, MAP2K1, MAP2K2, NF1, NRAS, PPP1CB, PTPN11, RAF1, RASA2, RIT1, SHOC2, SOS1, SOS2,</i> and <i>SPRED1</i> and Del/Dup: <i>NF1</i> and <i>SPRED1</i> <input type="checkbox"/> SPD1-NG: NGS and Del/Dup: <i>SPRED1</i> only 	<input type="checkbox"/> NF2-NG: NGS and Del/Dup: <i>NF2</i> only <input type="checkbox"/> SCH-NG: NGS 3 genes: <i>LZTR1, NF2,</i> and <i>SMARCB1</i> Del/Dup: <i>NF2, LZTR1,</i> and <i>SMARCB1</i> <input type="checkbox"/> MEN-NG: NGS 4 genes: <i>NF2, SMARCB1, SMARCE1,</i> and <i>SUFU</i> Del/Dup: <i>NF2</i> and <i>SMARCB1</i>
Tuberous Sclerosis Complex	Peripheral Nerve Sheath Tumor Testing
<input type="checkbox"/> TSCP-NG: NGS and Del/Dup: <i>TSC1</i> and <i>TSC2</i> only	<input type="checkbox"/> PNT-NG: NGS 6 genes: <i>NF1, NF2, KRAS, LZTR1, PTPN11</i> and <i>SMARCB1</i>; Del/Dup: <i>NF1, NF2, LZTR1,</i> and <i>SMARCB1</i>
Capillary Malformation Arteriovenous Malformation Syndrome	Rhabdoid Tumor Predisposition Syndrome
<input type="checkbox"/> RASA-NG: NGS and Del/Dup: <i>RASA1</i> only	<input type="checkbox"/> RT-NG: NGS and Del/Dup: <i>SMARCB1</i> only
Important points of consideration for testing	
<p>The MGL offers next generation sequencing testing options that provide the ability to identify variants (indels and substitutions) as low as 3% of the alleles, depending on coverage in the regions of interest.</p> <p>The average coverage of our panel is >1800x. Specifically for the <i>NF1</i> gene, the NGS array covers >99.8% of the <i>NF1</i> coding region at ≥350X and 100% ≥200X, allowing detection of very low level mosaicism, down to 3-5% MAF respectively (regions covered by ≥350X respectively ≥200X).</p> <p>For all remaining genes on our panels, the NGS array covers >99.5% of the coding region at ≥350X and 99.2% covered at ≥200X. Remaining regions are covered at ≥30X.</p> <p>For additional testing options via tumor/biopsy, please see page 3 of this order form. Please contact the lab via phone (205) 934-5562 or via email at medgenomics@uabmc.edu if you have any questions when completing this form. For additional information, please visit our website at www.genetics.uab.edu/medgenomics.</p>	
Specimen requirements vary based on test requested; please see www.genetics.uab.edu/medgenomics for more details.	
Date collected:	
<input type="checkbox"/> Peripheral Blood (EDTA); # Tubes:	<input type="checkbox"/> Saliva (kit must be provided by MGL)
<input type="checkbox"/> Extracted DNA; Source:	<input type="checkbox"/> Other, please describe:



UAB MEDICAL GENOMICS LABORATORY 720 South Twentieth Street, Suite 330 Tel: (205) 934-5562 Birmingham, Alabama 35294-0005 Fax: (205) 996-2929 www.genetics.uab.edu/medgenomics		Accession: For MGL Laboratory Use only	
Patient Name: (First) (MI) (Last)		DOB: (MM/DD/YY)	
Tumor/Biopsy Based Comprehensive Testing			
Key used below: Next Generation Sequencing (NGS) Sanger Sequencing (Sanger) Deletion/Duplication analysis (Del/Dup)			
NF1/SPRED1 on biopsied CALs and Neurofibromas		NF2/Schwannomatosis/Meningiomatosis (Please choose testing options based on correct specimen)	
<input type="checkbox"/> NF14C: Sanger and Del/Dup: NF1 and SPRED1 on biopsied CALs <input type="checkbox"/> NF14N: Sanger and Del/Dup: NF1 on biopsied neurofibromas **Please contact the laboratory at least one week in advance of the biopsy before ordering this test as media must be provided in advance and special shipping instructions apply.**		Fresh/Frozen Tumor <input type="checkbox"/> NF2-NG: NGS and Del/Dup: NF2 only <input type="checkbox"/> SCH-NG: NGS 3 genes: LZTR1, NF2, and SMARCB1 and Del/Dup: NF2, LZTR1, and SMARCB1 <input type="checkbox"/> MEN-NG: NGS 4 genes: NF2, SMARCB1, SMARCE1, and SUFU; Del/Dup: NF2 & SMARCB1	
Peripheral Nerve Sheath Tumor Testing		Tumor Block	
<input type="checkbox"/> PNT-NG: NGS 6 genes: NF1, NF2, KRAS, LZTR1, PTPN11, and SMARCB1; Del/Dup: NF1, NF2, LZTR1, and SMARCB1 on Fresh/Frozen Tumor		<input type="checkbox"/> NF24: Sanger and Del/Dup: NF2 <input type="checkbox"/> SCHP: Sanger and Del/Dup: NF2, LZTR1, and SMARCB1	
Tuberous Sclerosis Complex		Rhabdoid Tumor Predisposition Syndrome	
<input type="checkbox"/> TSCP-NG: NGS and Del/Dup: TSC1 & TSC2 on Fresh/Frozen Tumor		Fresh/Frozen Tumor <input type="checkbox"/> RT-NG: NGS and Del/Dup: SMARCB1	
		Tumor Block <input type="checkbox"/> SB14RT: Sanger and Del/Dup: SMARCB1	
<input type="checkbox"/> Please check here if blood is provided for confirmation testing.			
Important points of consideration for testing			
When proceeding with biopsy based testing for NF1, RNA-based tissue culture analysis would be the suggested starting point. Please contact the laboratory before ordering this test as media must be provided in advance.			
The MGL offers next generation sequencing testing options that provide the ability to identify variants (indels and substitutions) as low as 3% of the alleles, depending on coverage in the regions of interest.			
When proceeding with tumor based testing for NF2, test code "SCH-NG" (NF2, SMARCB1, and LZTR1) is suggested unless the patient also has additional findings unique to NF2.			
Please contact the lab via phone (205) 934-5562 or via email at medgenomics@uabmc.edu if you have any questions when completing this form. For additional information, please visit our website at www.genetics.uab.edu/medgenomics .			
Specimen requirements vary based on test requested; please see www.genetics.uab.edu/medgenomics for more details.			
Date collected:			
<input type="checkbox"/> Peripheral Blood (EDTA); # Tubes:		<input type="checkbox"/> Saliva (kit must be provided by MGL)	
<input type="checkbox"/> Extracted DNA; Source:		<input type="checkbox"/> Other, please describe:	
<input type="checkbox"/> Biopsy-CAL-spot; # biopsies:		<input type="checkbox"/> Biopsy-Neurofibroma; # biopsies:	
<input type="checkbox"/> Tumor (specify location on checklist): <input type="checkbox"/> Frozen <input type="checkbox"/> Fresh <input type="checkbox"/> Paraffin Block <input type="checkbox"/> Paraffin Curls			
Pathology:			



UAB MEDICAL GENOMICS LABORATORY 720 South Twentieth Street, Suite 330 Tel: (205) 934-5562 Birmingham, Alabama 35294-0005 Fax: (205) 996-2929 www.genetics.uab.edu/medgenomics		Accession: For MGL Laboratory Use only
Patient Name: (First) (MI) (Last)		DOB: (MM/DD/YY)
Sanger Testing from Blood/Saliva/DNA		
If multiple tests are requested, please specify order in which testing should be performed.		
Acceptable Specimen Types <ul style="list-style-type: none"> • Blood, (3-6ml EDTA; no time limitations associated with receipt) • Saliva, (OGR-575 DNA Genotek; kits are provided upon request) • DNA, , (extracted from lymphocyte cells, a minimum of 25ul at 3µg, O.D. value at 260:280nm ≥1.6, must be extracted in a CLIA or equivalent certified lab) • Fibroblasts 		Key used below: Sanger Sequencing (Sanger) Deletion/Duplication analysis (Del/Dup)
NF1/SPRED1 and Other RASopathy Related Conditions		Von Hippel Lindau
<input type="checkbox"/> NF1-R: Sanger and Del/Dup: <i>NF1(RNA)</i>		<input type="checkbox"/> VHL1: Sanger & Del/Dup: <i>VHL</i>
<input type="checkbox"/> NFSP1-R: Sanger and Del/Dup: <i>NF1(RNA)</i> & <i>SPRED1 (gDNA)</i>		PTEN Related Disorders
<input type="checkbox"/> CST1: Sanger: <i>HRAS (gDNA)</i>		<input type="checkbox"/> PTEN1: Sanger and Del/Dup: <i>PTEN</i>
Autosomal Recessive Polycystic Kidney Disease		Fragile X syndrome
<input type="checkbox"/> PKDL: Linkage Analysis for informativity		<input type="checkbox"/> FRX: PCR and Southern Blot analysis: <i>FMRI</i>
<input type="checkbox"/> PKDPL: Prenatal Linkage		Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)
PARENT: Father's Name and DOB (mm/dd/yyyy): _____		<input type="checkbox"/> MCD1: Targeted analysis of exon 11: <i>ACADM</i>
PARENT: Mother's Name and DOB (mm/dd/yyyy): _____		<input type="checkbox"/> MCD2: Sanger: <i>ACADM</i>
		Other (Please contact laboratory before selecting this testing option)
Known Mutation Testing		
<input type="checkbox"/> KT2: Targeted detection of a specific, previously identified known mutation in any gene that is available at our lab by Sanger sequence, MLPA, and/or FISH analysis (Complete Previous Testing History: Page 1)		
<input type="checkbox"/> PT2: Prenatal testing (Complete Previous Testing History: Page 1)		
<input type="checkbox"/> MCC: Blood specimen for mother provided for maternal cell contamination studies (required)		
<input type="checkbox"/> RT2: Targeted RNA based testing for VOUS found during Next Generation Sequencing (Complete Previous Testing History: Page 1)		
<input type="checkbox"/> KT2-NGS: Targeted testing for a known mutation with deep coverage of the alleles and detection of mosaicism for a mutation present in at least 3-5% mutant allele fraction (MAF) (Complete Previous Testing History: Page 1)		
Important points of consideration for testing		
For additional testing options via tumor/biopsy, please see page 3 of this order form. Please contact the lab via phone (205) 934-5562 or via email at medgenomics@uabmc.edu if you have any questions when completing this form. For additional information, please visit our website at www.genetics.uab.edu/medgenomics .		
Specimen requirements vary based on test requested; please see www.genetics.uab.edu/medgenomics for more details.		
Date collected:		
<input type="checkbox"/> Peripheral Blood (EDTA); # Tubes:	<input type="checkbox"/> Saliva (kit must be provided by MGL)	
<input type="checkbox"/> Extracted DNA; Source:	<input type="checkbox"/> Other, please describe:	
Prenatal Testing		
<input type="checkbox"/> Amniotic Fluid	<input type="checkbox"/> Cultured Amniocytes	
<input type="checkbox"/> Direct CVS (cleaned)	<input type="checkbox"/> Cultured Villus Cells	
Location of back-up culture (required):		



UAB MEDICAL GENOMICS LABORATORY 720 South Twentieth Street, Suite 330 Birmingham, Alabama 35294-0005 www.genetics.uab.edu/medgenomics		Tel: (205) 934-5562 Fax: (205) 996-2929		Accession: For MGL Laboratory Use only	
Patient Name: (First) (MI) (Last)			DOB: (MM/DD/YY)		
Billing					
<input type="checkbox"/> Please hold sample until further notice from the ordering facility.					
<p>By completing this form, you agree that you have discussed the MGL's billing policies with your patient. As insurance prices are not listed on the internet, please call the billing coordinator at 205-934-5523 to request a quote, if needed, and pass this information along to the client. Credit card information MUST be provided with sample submission for self-pay clients. Full information on the billing policies is available at www.genetics.uab.edu/medgenomics.</p>					
Please note: If you are paying via self-payment or desiring a benefits investigation, there will be a 3-5 business day delay on the initiation of your test					
<input type="checkbox"/> Institutional Bill Please check box if billing institution should receive report directly: <input type="checkbox"/>					
Institution:			PO#		
Address:					
City:		State:		Zip:	
Contact:			Contact Title:		
Email:		Phone:		Fax:	
<input type="checkbox"/> Payment Enclosed <input type="checkbox"/> Visa <input type="checkbox"/> MasterCard <input type="checkbox"/> Discover <input type="checkbox"/> American Express					
Name as it appears on card:					
Card Number:					
Expiration Date:			3-digit Security code:		
Cardholder Signature:					
Cardholder Email Address:					
<input type="checkbox"/> Bill Third Party Insurance Company Insurance pre-verification/authorization previously performed? <input type="checkbox"/> Yes <input type="checkbox"/> No					
<u>Please Note: Out of State Medicaid is not accepted under any circumstances</u>					
ICD-10 Diagnosis Codes (required):					
Please send a legible copy of the patient's insurance card, front and back. All RUSH fees must be paid up front.					
For a list of contracted insurance companies, please visit our website at www.genetics.uab.edu/medgenomics or call our billing coordinator at 205-934-5523.					
The MGL will contact the insurance provider to inquire regarding the CPT code coverage for all samples submitted for insurance payment. The provider will be contacted if: a) the insurance provider denies coverage of the requested codes b) supporting documents are required from the provider to confirm coverage c) a copay/deductible is expected to exceed \$500. This service is not completed on prenatal samples. Please note: An insurance verification is not a guarantee of payment.					
<input type="checkbox"/> Please check box if you would not like this service to be performed by the MGL.					
Please include a copy of the pre-approval statement or provide the approval number if payment has been pre-authorized in advance of shipment. Approval Number:					



MEDICAL GENOMICS LABORATORY: NF1/SPRED1 & RASOPATHIES PHENOTYPIC CHECKLIST FORM



Patient ID: _____

Referring Physician: _____ Date of Exam ___/___/___

DEMOGRAPHIC INFORMATION

Gender: Male Female

Date of Birth: ___/___/___

Ethnicity: Mother: White Black Native American Hispanic Asian Other:
Father: White Black Native American Hispanic Asian Other:

DIAGNOSIS

Clinical diagnosis: NF1 Multiple CAL spots-only
 Spinal NF Familial multiple CAL spots-only
 NF Noonan Legius syndrome
 Segmental NF1 Isolated neurofibromas
 Noonan syndrome Single NF1 feature
 Noonan syndrome with multiple lentiginos (LEOPARD) syndrome
 Cardio-facio-cutaneous syndrome (CFC)
 Costello syndrome Unknown

NF1 NIH criteria:
 >6 CAL spots >5mm, postpubertal >15mm Optic glioma
 >2 neurofibromas or 1 plexiform NF >2 Lisch nodules
 Axillary or inguinal freckling A distinct osseous lesion
 First degree relative diagnosed with NF1 by above criteria
Does patient fulfill NIH diagnostic criteria for NF1? Yes No

Family history: Sporadic (proband is a "founder") Familial (proband is a "non-founder") Unknown
Consanguinity: Yes No Unknown

GENERAL INFORMATION

Height: ___ cm (Short stature) Head circumference: ___ cm (Macrocephaly) Weight: ___ kg

Clinical Features

Craniofacial: Absent Unknown Hypertelorism
 Macrocephaly Bitemporal narrowing Low set / rotated ears
 Palpebral ptosis Low posterior hairline Downslanting palpebral fissures
 Midface hypoplasia Short / webbed neck
 Other: _____

Ectodermal: Please provide detail on size/ location of the CAL-spots and other hyper/hypopigmentation areas on figure page 3

Absent Unknown Hair abnormalities
 Deep palmar/plantar creases Dry/hyperkeratotic skin Other: _____
 Multiple nevi / lentiginos Abnormal/sparse eyebrows

Café-au-lait spots: 0 1-5 ≥6 to 100 >100

General impression on the borders of the CAL-spots:

typical well-defined smooth borders diameter:
 irregular margins, ragged borders diameter:

Skin fold freckling: None Unknown

Comments (e.g. very faint, etc):

Groin	Left	Right	_____
Axilla	<input type="checkbox"/>	<input type="checkbox"/>	_____
Submammary	<input type="checkbox"/>	<input type="checkbox"/>	_____



MEDICAL GENOMICS LABORATORY: NF1/SPRED1 & RASOPATHIES PHENOTYPIC CHECKLIST FORM



Lisch nodules: None Unknown Left Right

Neurofibromas:

Cutaneous neurofibromas (soft nodules that project above the skin):

Histopathologically confirmed: Y / N

0 1 2-6 6-99 100-500 >500

Intradermal neurofibromas (soft depression within the skin w/ pinkish overlying discoloration):

Histopathologically confirmed: Y / N

0 1 2-6 6-99 100-500 >500

Subdermal neurofibromas (firm nodules palpable underneath the skin):

Histopathologically confirmed: Y / N

0 1 2-6 6-99 100-500 >500

Plexiform neurofibromas:

Histopathologically confirmed: Y / N

None

Visible from outside

Internal

With hyperpigmentation

Without hyperpigmentation

Head

Neck

Trunk

L Arm

L Hand

L Leg

L Foot

Abdomen

Pelvis

Genital area

R Arm

R Hand

R Leg

R Foot

Spinal neurofibromas (arising from the spinal dorsal nerve root): If present, please provide detail on figure page 3

Histopathologically confirmed: Y / N

Unknown Absent by MRI

Present, asymptomatic

Present, symptomatic

unilateral bilateral;

C_____ T_____, L_____, S_____ regions.

Other neoplasms:

Absent

Unknown

Optic glioma:

Absent by MRI

Present by MRI, **symptomatic**

Present by MRI, **asymptomatic**

Nerve (L and/or R)

Chiasm

Hypothalamic glioma

Brainstem glioma

Other glioma

MPNST

JMML

Rhabdomyosarcoma

Pheochromocytoma

Colonic polyps

Lipoma

schwannoma

meningioma

juvenile xanthogranuloma

breast cancer

Other, specify: _____

Skeletal:

Absent

Unknown

Long bone dysplasia

Pseudarthrosis

Sphenoid wing dysplasia

Bone cysts

scoliosis

Dysplastic vertebrae

pectus excavatum

pectus carinatum

Cubitus valgus

Broad chest / telethelia

Other: _____

Cardiovascular:

Absent

Unknown

Present:

Hypertension

Aortic stenosis Renal artery stenosis

Moya moya

Pulmonary valve stenosis

Arrhythmia

Hypertrophic cardiomyopathy

Atrial septal defect

Ventricular septal defect

ECG anomalies

Mitral valve anomaly

Unknown

Other _____

Development:

Normal for age

Delayed for age

Hypotonic

Hypertonic

Gross Motor Delays

Fine Motor Delays

ADD

Speech Delays

Hyperactivity

Learning disability

Unknown

Exam not done

Other: _____

IQ: Full scale _____, **Verbal** _____, **Performance** _____.



MEDICAL GENOMICS LABORATORY: NF1/SPRED1 & RASOPATHIES PHENOTYPIC CHECKLIST FORM




Education: Too young for school At or above age level Below age level Unknown
 HS completion College graduate Higher degree

Hematological: abnormal hemostasis Factor XI deficiency Other: _____ Unknown

Segmental NF phenotype: Absent Possible

Please indicate location/size of pigmentary lesions and/or neurofibromas



Indicate size and location of


Neurofibromas 

CAL-spots 

Freckling 

Hyperpigmented region 

Please indicate location of spinal tumors (if present)



Additional comments/remarks:



Informed Consent for Genetic Testing

This form does not need to be returned to the Medical Genomics Laboratory if Informed Consent portion of the Test Request form has been signed.

I hereby consent for:

Name:	DOB:	Gender:
-------	------	---------

To participate in genetic testing for the following RNA/DNA-based cascade of tests ordered by my physician at the University of Alabama at Birmingham (UAB) Medical Genomics Laboratory (MGL):

Genetic Tests:

I understand that:

1. Any biological samples submitted for genetic testing (e.g., blood, cheek cells, saliva, amniotic fluid, chorionic villi, tumor, and/or tissue) will be removed from me and/or my minor child(ren) using standard techniques which carry their associated risks.

2. Any samples obtained will be used for the purpose of attempting to determine if I and/or members of my family carry genetic changes in the disease genes ordered by my physician.

3. The genetic tests performed at the MGL are the most sensitive developed and are highly specific. However, sensitivity and specificity are test-dependent. Additional testing details and the specific detection rates of each test can be found at www.genetics.uab.edu/medgenomics.

4. The following are possible outcomes for the specific tests listed above:

Positive	Unknown Significance	Negative
This is an indication that I may be predisposed to or have the specific disease, or condition tested. Further testing may be needed to confirm the diagnosis.	There may be a possibility that the laboratory findings will be ambiguous or of unknown significance. This may require additional testing from me or my family members. In rare circumstances, findings may be suggestive of a condition different than the diagnosis that was originally made.	There is a chance that I will still have this genetic condition even though the genetic test results are negative. Due to limitations in technology and incomplete knowledge of genes, some changes in RNA/DNA or protein products that cause disease may not be detected by this test.

5. In other cases, the RNA/DNA test is unable to identify an abnormality although the abnormality may still exist. This event may be due to incomplete knowledge of the gene structure or an inability of current technology to identify certain types of mutations in the gene. When clinically necessary, the MGL may use a method called linkage analysis. This method is not a direct test, but will report the probability that you and/or family members have an inherited disease or disorder. In some families, the markers used in linkage analysis may be uninformative. If so, linkage testing cannot provide results for the family members in question.

6. The RNA/DNA analysis performed by the MGL is specific for the genetic test listed above and in no way guarantees my health or the health of my living or unborn children. The MGL cannot be responsible for an erroneous clinic diagnosis made elsewhere.

7. The tests performed at the MGL are expanded and improved continuously. The tests offered are not considered research but are considered the best and newest laboratory service that can be offered. Genetic testing is complex and utilizes specialized materials so there is always some very small possibility that the test will not work properly or that an error will occur. There is a low error rate (perhaps 1 in 1000 samples) even in the best laboratories. Additionally, in very rare instances, this test may reveal an important genetic change that is not directly related to the clinical reason for ordering this test. This would be considered an incidental finding. The MGL reserves the right to report these incidental findings if they are clinically relevant to the patients and/or their families. In such instances, these results will be discussed with my healthcare provider and additional testing may be recommended. My signature acknowledges my voluntary participation in this test, but in no way releases the laboratory and staff from the MGL from their professional or ethical responsibility to me.

8. The MGL does not return DNA samples to individuals or physicians. While the MGL is not a specimen banking facility, in some cases it may be possible for the laboratory to reanalyze my remaining DNA upon request. The request for additional studies must be ordered by my referring physician/counselor and there will be an additional fee.



